

CHAGAS TESA

Now available for your Lab routine

CHAGAS TESA VIRCLIA® IgG+IgM MONOTEST

Indirect chemiluminescent immunoassay (CLIA)
to detect specific IgG + IgM antibodies against
Trypanosoma cruzi excretory-secretory antigens (TESA)
in human serum or plasma samples.

- First commercial TESA native antigen kit.
- Exo-antigen present in the infective form of *T. cruzi*, both in the acute and chronic phases.
- **Multiple uses:** useful test for screening, as a second test in parallel and also for disease monitoring.
- Excellent clinical sensitivity and specificity.
- **Compatible with the rest of the VirClia® panel**, which offers more than 90 infectious disease parameters in CLIA monotest format.
- **A complete solution:** assay that complements Vircell's panel of tests based on crude (IFA) and recombinant antigens (ELISA and VirClia®).



VirClia® MONOTEST - 24 tests

VirClia® Lotus

Fundamentals

Numerous scientific studies demonstrate the enormous usefulness of TESA antigens as an aid in the diagnosis of Chagas disease. Its high sensitivity and specificity excel in comparison with other native or recombinant antigens of *T. cruzi*¹².

TESA antigens provide great value in the follow-up of infected patients, since their antibody titers show high correlation with the treatment and prognosis of the disease. Until now, the use of TESA antigens was limited to research centers that produce them by themselves for in-house testing.

CHAGAS TESA VIRCLIA[®] IgG+IgM MONOTEST is the first automated TESA-based monotest assay for routine laboratory use. The simultaneous use of CHAGAS TESA VIRCLIA[®] and CHAGAS VIRCLIA[®] makes it possible to solve the diagnosis of the disease at the same time, with native and recombinant antigens, following the WHO recommendations.

Performance

The clinical sensitivity and specificity were determined by testing 276 samples against a commercial ELISA kit.

No. of samples	Sensitivity	Specificity
276	95%	100%

¹ Berrizbeitia, M. et al. 2013. Trypomastigote of *Trypanosoma cruzi* EXCRETED/SECRETED ANTIGENS (TESA) as useful tools for the diagnosis of Chagas disease. *Saber, Universidad de Oriente, Venezuela*. Vol. 25 N° 4: 346-357.

² Sguassero Y. et al. 2015. Course of Chronic *Trypanosoma cruzi* Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies. *PLoS ONE* 10(10): e0139363. doi:10.1371/journal.pone.0139363.z

The True Monotest

- On-demand testing: **One monotest= one reportable test.** Nothing else is required.
- **Individual Quality Control per monotest**, no need for extra controls or calibrations.
- **Random Access automated protocol** with results in 1 h.
- **Same day results**, no batching, no sample cumulation.



Clinical Benefits

- Initial screening test due to its high sensitivity and specificity.
- Test in parallel with recombinant antigen-based assays as recommended by WHO.
- Third opinion test to resolve discrepancies.
- Follow-up of patients treated with anti-parasitic drugs.



**TESA NATIVE
ANTIGEN**



**AUTOMATED
RESULTS IN
1 HOUR**



**COMPLETE
SOLUTION**



**TREATMENT
FOLLOW-UP**



**BETTER
PATIENT CARE**

Ordering information and related products

Reference	Description	Type	Content
VCM099	CHAGAS TESA VIRCLIA [®] IgG+IgM MONOTEST NEW	TESA native antigen	24 tests
VCM008	CHAGAS VIRCLIA [®] IgG+IgM MONOTEST	Recombinant antigen	24 tests
T1023	CHAGAS TESA ELISA IgG+IgM NEW	TESA native antigen	96 tests
T1020	CHAGAS ELISA IgG+IgM	Recombinant antigen	96 tests
PCHAG	CHAGAS IFA IgG+IgM	Native crude antigen	100 tests
VSP031	CHAGAS VIRCLIA [®] IgG+IgM SAMPLES	-	24 tests

Vircell S.L.

Parque Tecnológico de la Salud, Avicena 8, 18016 Granada, Spain
info@vircell.com www.vircell.com